-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

Benzinga·09/21/2026 17:38:50
语音播报
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.